Forecast

The analysts' average price target is €12.52 (+1,103.85%). The median is €12.52 (+1,103.85%).

Buy	4
Hold	1
Sell	0

News Go to news feed

Metagenomi presents compact CRISPR tool MG119-28 with high editing efficiency in Nature

Metagenomi introduces MG119-28 in a study in Nature Structural & Molecular Biology — a compact Cas12f nuclease that the researchers report shows faster DNA cleavage and improved editing efficiency due to greater protein stability and a more stable guide RNA. The study, conducted with the University of Texas at Austin, builds on proof-of-concept data that demonstrated a 64% reduction of the Atxn2 protein in mice after AAV administration. The company is evaluating applications beyond hepatic indications, while the clinically active biotech, with a market value of $54 million, continues to burn cash and carries the typical development risks. » More on de.investing.com
Metagenomi renames itself and focuses gene‑therapy program for hemophilia A

Metagenomi has completed its rebranding and is prioritizing preclinical in‑vivo therapeutics, foremost the hemophilia A program MGX-001, which the company says showed curative factor VIII activity in non‑human primates without identifiable off‑target effects. After a pre‑IND meeting, Metagenomi plans to file IND/CTA applications in Q4 2026. The company expects financial runway into Q4 2027, reports more cash than debt but continues to burn cash; analysts see price targets of $7–12. » More on de.investing.com
Metagenomi: MGX-001 shows curative potential in primate study for hemophilia A

Metagenomi reports that its experimental gene therapy MGX-001 demonstrated therapeutically relevant factor VIII activity in a dose‑finding study in non‑human primates; five of six dose cohorts achieved significant results and the dose intended for clinical use produced an average of 49% FVIII activity (range 29.3–59.5%). The treatment was generally well tolerated, with transient liver enzyme elevations only at the highest LNP dose. Metagenomi plans a pre‑IND meeting in Q4 2025 and aims to file IND/CTA applications by the end of 2026, while undergoing a restructuring that will cut 25% of its workforce. The company is trading at a market capitalization of USD 80.7 million; an analysis by InvestingPro rates Metagenomi as undervalued despite a lack of profitability. » More on de.investing.com

Financials

In the last quarter, Metagenomi had revenue of -€225.19K and net profit of -€24.08M

(EUR)	Jun 2026	YoY
Revenue	-225.19K	103.12%
Gross profit	-225.19K	98.10%
Net profit	-24.08M	42.57%
EBITDA	-22.97M	46.13%

Fundamentals

Metric	Value
Market capitalization	€39.32M
Number of shares	37.65M
52-week high/low	€3.41 - €0.98
Dividends	No
Beta	0.67
P/E ratio	-0.49
PEG ratio	0.08
P/B ratio	0.40
P/S ratio	3.36

Company profile

Metagenomi, Inc. ist ein Biotechnologieunternehmen im Bereich des Gen-Editings und entwickelt in den Vereinigten Staaten Therapeutika für Patienten unter Verwendung der aus der Metagenomik abgeleiteten Genome-Editing-Toolbox. Die Genom-Editierungs-Toolbox des Unternehmens umfasst programmierbare Nukleasen, Basen-Editoren und RNA- und DNA-vermittelte Integrationssysteme, wie z. B. Prime-Editierungssysteme und mit "clustered regularly interspaced short palindromic repeat-associated transposases". Es hat ein strategisches Kooperations- und Lizenzabkommen mit ModernaTX, Inc. mit Schwerpunkt auf neuen Genome-Editing-Systemen für therapeutische In-vivo-Anwendungen beim Menschen; ein Entwicklungs-, Options- und Lizenzabkommen mit Affini-T Therapeutics, Inc. zur Entwicklung und Vermarktung von gen-editierten T-Zell-Rezeptor-basierten therapeutischen Produkten im Bereich der Behandlung, Prävention oder Diagnose von menschlichem Krebs; und ein Kooperations- und Lizenzabkommen mit Ionis Pharmaceuticals, Inc. zur Erforschung, Entwicklung und Vermarktung von Prüfmedikamenten unter Verwendung von Genome-Editing-Technologien. Das Unternehmen wurde im Jahr 2016 gegründet und hat seinen Sitz in Emeryville, Kalifornien.